It has been reported that germline BRCA1/2 mutations occur in approximately 10 to 20% of patients with invasive epithelial ovarian cancers [7, 9–14, 19–22], and more than 20% of patients with high-grade serous ovarian cancer [12]. The gene discussed is BRCA1; the disease is ovarian carcinoma.